Peapod Lane Capital LLC Purchases New Holdings in Chimerix, Inc. (NASDAQ:CMRX)

Peapod Lane Capital LLC bought a new position in Chimerix, Inc. (NASDAQ:CMRX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 754,566 shares of the biopharmaceutical company's stock, valued at approximately $2,626,000. Chimerix comprises approximately 2.6% of Peapod Lane Capital LLC's holdings, making the stock its 11th biggest holding. Peapod Lane Capital LLC owned 0.84% of Chimerix as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Valeo Financial Advisors LLC boosted its stake in shares of Chimerix by 566.9% in the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company's stock valued at $76,000 after purchasing an additional 69,505 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in Chimerix by 66.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company's stock worth $321,000 after purchasing an additional 138,098 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in Chimerix by 154.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company's stock valued at $2,846,000 after buying an additional 496,823 shares during the period. Finally, Stoneridge Investment Partners LLC grew its stake in shares of Chimerix by 22.5% during the fourth quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company's stock valued at $154,000 after buying an additional 8,134 shares during the last quarter. 45.42% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on CMRX shares. Wedbush reissued an "outperform" rating and issued a $6.00 target price on shares of Chimerix in a research note on Tuesday, December 10th. HC Wainwright reiterated a "buy" rating and issued a $11.00 price objective on shares of Chimerix in a research report on Monday, December 30th.

Chimerix Price Performance

Chimerix stock traded down $0.18 during trading hours on Monday, reaching $4.38. The stock had a trading volume of 1,216,842 shares, compared to its average volume of 1,344,052. Chimerix, Inc. has a 52 week low of $0.75 and a 52 week high of $4.65. The stock has a market cap of $393.94 million, a PE ratio of -4.66 and a beta of 0.35. The company has a fifty day simple moving average of $3.53 and a 200-day simple moving average of $1.83.

Insiders Place Their Bets

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the business's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the transaction, the chief executive officer now directly owns 609,603 shares of the company's stock, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders sold 20,760 shares of company stock worth $91,175. 13.10% of the stock is currently owned by company insiders.

Chimerix Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.